Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
KINEX PHARMACEUTICALS LLC
Jurisdiction of Incorporation/Organization
DE
Year of Incorporation/Organization
Over Five Years Ago
Entity Type
LIMITED LIABILITY COMPANY
Item 2 Issuer Principal Place of Business and Contact Information
701 ELLICOTT STREET
BUFFALO, NY 14203
Phone Number:
subscription required
Item 3. Related Persons
Name
FLINT BESECKER
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JOHNSON LAU
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
JEAN-PIERRE SOMMADOSSI
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
CHARLES LANNON
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JINN WU
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
DAVID HANGAUER
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
LYN DYSTER
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
BIOTECHNOLOGY
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
$1,000,001 - $5,000,000
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
07/30/2012
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
25000
Item 13. Offering and Sales Amounts
Total Offering Amount
40000000
Total Amount Sold
5000000
Total Remaining to be Sold
35000000
Clarification of Response
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
1
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
500000.0 Is an estimate
Clarification of Response
EXECUTIVE OFFICER SALARIES
Signature and Submission
Issuer Name
KINEX PHARMACEUTICALS LLC
Issuer Signature
LYN DYSTER
Signer Name
LYN DYSTER
Signer Title
VICE PRESIDENT
Signature Date
08/06/2012